2002 Fiscal Year Final Research Report Summary
Study of human uroplakin in various diseases of urinary tract
Project/Area Number |
13671648
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Urology
|
Research Institution | The Department of Urology, Faculty of Medicine, Shiga University of Medical Science |
Principal Investigator |
KATAOKA Akira Assistant, The Department of Urology, Faculty of Medicine, Shiga University of Medical Science, 医学部, 助手 (80293835)
|
Co-Investigator(Kenkyū-buntansha) |
KIM Chol-jang Assistant Professor, The Department of Urology, Faculty of Medicine, Shiga University of Medical Science, 医学部, 講師 (10204968)
WAKABAYASHI Yoshihiko Assistant Professor, The Department of Urology, Faculty of Medicine, Shiga University of Medical Science, 医学部, 講師 (80191724)
YOSHIKI Tatsuhiro Associate Professor, The Department of Urology, Faculty of Medicine, Shiga University of Medical Science, 医学部, 助教授 (80230704)
OKAMOTO Keisei Assistant, The Department of Urology, Faculty of Medicine, Shiga University of Medical Science, 医学部, 助手 (50303780)
JOHNIN Kazuyoshi Assistant, The Department of Urology, Faculty of Medicine, Shiga University of Medical Science, 医学部, 助手 (90324590)
OKADA Yusaku Professor, The Department of Urology, Faculty of Medicine, Shiga University of Medical Science (20127062)
|
Project Period (FY) |
2001 – 2002
|
Keywords | Transitional cell / Uroplakin / Tumor marker / Bladder cancer / Renal pelvic cancer / Vesicoureteral reflux |
Research Abstract |
Uroplakins (UPs) la, lb, II, and III are tissue-specific and differentiation-dependent transmembrane proteins of the urothelium. We assessed the usefulness of human UP la as a histological marker by examining its expression in urinary bladder transitional cell carcinoma (TCC). A polyclonal antibody against human UP la was raised using a synthesized polypeptide. We applied our antibody to various organ tissues including urothelium and observed no crossreactivity. Analysis by RT-PCR of normal urothelium, TCC and other organ tissues indicates that the human UP la gene expression is highly specialized to urothelium, and conserved in TCC. Using immunohistochemistry, we investigated the expression of UP la in TCC from patients who had undergone radical cystectomy and from autopsy cases. Positive staining (10% or more positive cancer cells) was noted in primary lesions from 61 of 63 (96.8%) cystectomy patients. Depending on pathological grade, high expression (50% or more positive cancer cells) was observed in 17 of 18 (94.4%) moderately- to well-differentiated TCC and in 36 of 45 (80.0%) poorly differentiated TCC. With regard to tumor invasion, high-expression was noted in 20 of 22 (90.9%) superficial and 33 of 41 (80.5%) muscle-invasive TCC. Cause-specific survival rates were 68.6% and 75.0% in high- and low-expression patients, respectively (log-rank test, P=0.855, mean follow-up ; 65.0 mo). In metastases, positive reactions were observed in 13 of 18 (72.2%) lesions, UP la may represent a specific histological marker judging from stable expression, although its value as a prognostic factor remains undetermined.
|
Research Products
(2 results)